Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC, 3083, Australia.
Int J Clin Pharm. 2021 Apr;43(2):386-393. doi: 10.1007/s11096-020-01026-z. Epub 2020 Apr 16.
Background Codeine is one of the most commonly used opioids worldwide and is available in different formulations, often combined with other simple analgesics. There is a growing concern of the potential harms associated with codeine misuse in the Australian community, and for this reason codeine containing analgesics have been upscheduled in Australia to 'prescription only medicines' from February 2018. There is currently limited knowledge on the views of Australian adults experiencing pain symptoms on this codeine restriction, and whether this change has impacted their ability to adequately manage their pain. Objective To investigate the views of adults experiencing pain on the 2018 codeine upscheduling in Australia. Setting Adults experiencing pain symptoms, predominantly recruited from Victoria, Australia. Method A descriptive cross-sectional study was conducted using a pre-tested customised anonymous self-administered questionnaire between January and March 2019. To capture a broad range of demographics, participants were recruited from ten Victorian community pharmacies across metropolitan Melbourne, Australia. Main outcome measure Opinions of Australian adults experiencing pain to targeted questions regarding the 2018 codeine upscheduling, including perceived advantages and disadvantages. Results A total of 120 participants completed the questionnaire. Sixty-two (52%) participants agreed/strongly agreed that codeine was helpful in alleviating pain symptoms before a prescription was required; while 43% of participants felt the codeine restriction has made it more difficult to manage their pain, with 33% unsure. Participants who were in favour of the codeine upscheduling believed that they are now more encouraged to consult healthcare professionals and make better use of the pain management services made available to them in the Australian community; however some now question the value of pharmacists in this context, given that there is now a reduced array of analgesic medicines available at pharmacies without a prescription. Conclusion This study showed there are mixed views, with some participants being unsure or not in favour of the codeine upscheduling, particularly based on qualitative responses. There is also opportunity in this space for healthcare providers to extend beyond standard practice and offer alternative pain management advice and support now that codeine is no longer available in Australian pharmacies without a prescription.
背景 可待因是世界上使用最广泛的阿片类药物之一,有多种制剂,通常与其他简单的镇痛药联合使用。澳大利亚社区中,人们越来越关注可待因滥用可能带来的危害,因此,自 2018 年 2 月起,含有可待因的镇痛药已被调整为“凭处方供应的药品”。目前,对于澳大利亚有疼痛症状的成年人对这种可待因限制的看法,以及这种变化是否影响了他们充分管理自身疼痛的能力,我们知之甚少。 目的 调查有疼痛症状的澳大利亚成年人对 2018 年澳大利亚可待因调整的看法。 地点 主要在澳大利亚维多利亚州招募有疼痛症状的成年人。 方法 2019 年 1 月至 3 月期间,我们采用预先测试的定制匿名自我管理问卷进行了描述性横断面研究。为了广泛了解人口统计学特征,我们在澳大利亚墨尔本大都市的十家维多利亚社区药房招募了参与者。 主要观察指标 对 2018 年可待因调整的目标问题,包括认为的优势和劣势,表达意见。 结果 共有 120 名参与者完成了问卷。62 名(52%)参与者同意/强烈同意在需要处方之前,可待因有助于缓解疼痛症状;而 43%的参与者认为可待因限制使他们更难以管理疼痛,其中 33%的人不确定。赞成可待因调整的参与者认为,他们现在更有动力咨询医疗保健专业人员,并更好地利用澳大利亚社区提供的疼痛管理服务;然而,一些人现在对药剂师在这种情况下的价值提出了质疑,因为现在没有处方的情况下,药店可提供的镇痛药种类减少了。 结论 这项研究表明,人们的看法存在分歧,一些参与者不确定或不赞成可待因调整,特别是根据定性回答。在这个领域,医疗保健提供者也有机会超越标准做法,提供替代的疼痛管理建议和支持,因为现在没有处方的情况下,可待因在澳大利亚的药店不再供应。